P.2.2 North Star ambulatory assessment in young DMD boys
Rita De Sanctis(Humanitas University), Eugenio Mercuri(Università Cattolica del Sacro Cuore), E. Mazzone(Università Cattolica del Sacro Cuore), Marika Pane(Università Cattolica del Sacro Cuore), Concetta Palermo(Università Cattolica del Sacro Cuore), Alessandra Graziano(Università Cattolica del Sacro Cuore), Serena Sivo(Università Cattolica del Sacro Cuore), F. Bianco(Ospedale Maggiore), Lavinia Fanelli(Università Cattolica del Sacro Cuore)
Cited by 0
Related Papers
Longitudinal effect of eteplirsen versus historical control on ambulation in <scp>D</scp> uchenne muscular dystrophy
|Annals of Neurology|2015|502
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178